110 results about "Lymphocytic cell" patented technology

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

This application relates to the technical field of pharmaceutical preparations, and specifically discloses a pharmaceutical composition containing ibrutinib and its preparation method. The composition includes the active ingredient ibrutinib, colloidal silicon dioxide, solubilizers, and other excipients such as excipients; its preparation method is: the active ingredient ibrutinib is preferentially mixed with colloidal silicon dioxide and solubilizers, followed by dry granulation, mixing, and capsule filling. The composition of this application can be used for the treatment of diseases such as mantle cell lymphoma (MCL) / chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, etc. It can effectively break the insoluble complex salt formed by ibrutinib and solubilizers, and has the advantages of fast dissolution rate and significantly improved bioavailability; in addition, the preparation method of this application has the advantages of good process reproducibility, simple process steps, low production cost, and being suitable for large-scale industrial production.

As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and / or for inclusion in a clinical trial using the agent to treat CLL.

A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and / or lymphoma associated diseases and / or malignancies.

The present invention discloses the use of an inhibitor anti-CD90.2, which can reduce the expression of innate lymphoid cells and thus can be used as an anti-pneumonia preparation targeting ILC for post-infarct pneumonia. The expression of ILC2 cells in patients with acute cerebral infarction increases. After the clearance of ILC, differential expression of pneumonia-related indicators is observed in patients with acute cerebral infarction, indicating that ILC2 promotes pneumonia after cerebral infarction. The inhibitor anti-CD90.2 (250 μg / mouse) was injected into Rag- / - mice 48 hours before modeling. The expression of ILC2 was measured 24 hours after MCAO modeling and was found to decrease, indicating that the inhibitor anti-CD90.2 can play an anti-pneumonia role by reducing the expression of ILC2 in mice with acute cerebral infarction. The present invention provides a new target for the prevention and treatment of pneumonia, a complication after acute cerebral infarction surgery. At the same time, it is proposed that the inhibitor anti-CD90.2 reduces the expression of ILC2 and thus can be used as an anti-pneumonia preparation targeting ILC2, achieving an effective combination of theoretical research and practical application.

The invention provides a construction method and a construction system of a chronic lymphocytic leukemia prediction model based on machine learning, electronic equipment and a storage medium, and relates to the field of chronic lymphocytic leukemia prognosis research. The construction method comprises the steps of obtaining original sample data, and performing preliminary screening; performing data cleaning on the screened sample data; determining a prediction factor from the plurality of features of the cleaned sample data; dividing the cleaned sample data corresponding to the prediction factor and the target variable into a training set and a test set; inputting the training set after unbalance processing into a LightGBM model for training to obtain a prediction model; inputting the test set into a prediction model, performing hyper-parameter optimization on the prediction model, and evaluating the performance of the prediction model; calibrating the prediction model to obtain a calibrated prediction model; the method has the beneficial effects that the method can be realized only by depending on conventionally available predictive factors, and the patient screening can be realized before the CLL clinical symptoms appear.

The present application relates to the fields of bioengineering and technology, and specifically to a method for resuscitating and culturing ROBO1CAR NK cells. The method comprises: resuscitating and culturing the cells using a resuscitation medium, wherein the resuscitation medium is a serum-free HIPP-T009 lymphocyte culture medium containing IL-2 and nicotinamide; performing a primary amplification culture on the resuscitated cells using a first amplification culture medium to obtain primary amplified cells; and performing a secondary amplification culture on the primary amplified cells using a second amplification culture medium to harvest the cells. The method can rapidly resuscitate frozen cells, effectively maintain cell growth and cell killing activity, and expand the culture scale, greatly reducing the culture cycle and production costs.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

Epigenetically modified DNA targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, are provided that bind to or target one or more target sites in the IL-2 gene or its regulatory elements in cells such as lymphoid cells (e.g., T cells). In some embodiments, the provided epigenetically modified DNA targeting systems modulate the phenotype or activity of lymphoid cells, or the function of lymphoid cells such as the phenotype or activity of T cells. In some embodiments, methods and uses relating to the provided compositions in the modulation of lymphoid cells such as T cells are also provided, for example, in connection with adoptive T cell therapy.

The present disclosure provides methods of treating a human subject suffering from lung cancer (e.g., non-small cell lung cancer (NSCLC)) using a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and synchronous chemoradiotherapy (CCRT, e.g., platinum-based dual drug chemotherapy (PDCT) and radiotherapy), a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody) is then used. In some aspects, the methods include a recovery phase that begins after completion of treatment with a PD-1 pathway inhibitor and CCRT, and ends at the beginning of treatment with a combination of a PD-1 pathway inhibitor and a LAG-3 antagonist.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Provided are methods for treating a subject of a solid tumor expressing GPC3 comprising administering to the subject an anti-GPC3 chimeric antigen receptor immunoresponsive cell wherein the administering is performed after or concurrently with subjecting the subject to a lymphopenia treatment. A kit for use in the method is also provided.

The invention relates to the technical field of dendritic cell in-vitro induction methods, and provides a dendritic cell body and an in-vitro induction method and application thereof. Thymic stromal lymphopoietin; the invention relates to a recombinant human FLT3L-Fc fusion protein. And maturing stimulation combination. On the premise of avoiding complex use of equipment, the bottlenecks of DC yield, subgroup purity and functionality are broken through.

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The present invention relates to the field of cell therapy, and specifically relates to a method for preparing a CAR-expressing T cell and a use. Disclosed in the present invention is a method for preparing a CAR-T cell, comprising the following steps: S1, collecting a T cell-containing cell population of an autologous or allogeneic donor of a subject; S2, administering lymphodepletion therapy to the subject for pretreatment; and S3, administering the T cell-containing cell population and a viral vector to the subject.

The present invention provides the use of isogaminol compounds in combination with glucocorticoids in the preparation of a leukemia treatment drug, belonging to the technical fields of biology and medicine. The isogaminol compounds described herein, when used in combination with glucocorticoids, can enhance the sensitivity of Jurkat cells to glucocorticoids, induce G1 cell cycle arrest in Jurkat cells, and induce apoptosis in Jurkat cells. The combined use of isogaminol compounds and glucocorticoids in the present invention provides a research foundation for overcoming glucocorticoid resistance in acute lymphoblastic leukemia.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The method (400) includes receiving an input tissue structure image (110), generating one or more lymphocyte density maps (125) inside the input tissue structure image by processing the input tissue structure image using a cell classification model (550), and identifying one or more TLS regions (135) inside the input tissue structure image by performing morphological image processing (130) on the one or more lymphocyte density maps. Each TLS region is represented by each cluster of lymphocyte cells. For each corresponding TLS region of the one or more TLS regions identified in the input tissue structure image, the method includes extracting each set of TLS features (140) from each cluster of lymphocyte cells, and classifying the corresponding TLS region as one of a first TLS maturation state, a second TLS maturation state, and a third TLS maturation state by processing each set of TLS features using a TLS classification model (350).

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

The utility model provides a cell separation tube for separating and extracting PBMC (peripheral blood mononuclear cells), and belongs to the technical field of biomedical instruments. In the use process of the cell separation tube, a blood sample can be injected into the cell separation tube along the fixing ring with the slope surface structure without inclining the separation tube body, and cannot be mixed with lymphocyte separation liquid due to too high injection speed. After centrifugal separation, the separated and extracted PBMC is located at the inner circle of the fixing ring, the contact area between the PBMC and a lymphocyte separating medium and a plasma layer is greatly reduced, more high-purity PBMC can be transferred by adopting a pipettor or a suction tube, other components in blood and the lymphocyte separating medium are prevented from being mixed into the PBMC, and the purity and the yield of the PBMC are improved. The cell separation tube is reasonable in structure, good in separation effect, capable of separating and extracting high-purity PBMC, and suitable for PBMC separation experiments.

The present disclosure provides a thymic stromal lymphopoietin (TSLP) binding molecule and uses thereof. The antibody disclosed by the invention is combined with different epitopes of Tezepelumab, and antibacterial peptide with antibacterial activity at the C terminal is not blocked, so that the capability of resisting external bacterial infection of TSLP is expected to be reserved. The antibody disclosed by the invention can be used for effectively inhibiting the activation effect of TSLP on STATs and JAK2 signal channels of an HTSLP Report Cell Line cell, and the inhibition activity of the antibody disclosed by the invention is superior to that of a reference antibody such as Tezepelumab. The antibody disclosed by the invention can effectively inhibit the proliferation promotion effect of TSLP on BaF3-TSLPR / IL7R alpha cells, and the inhibitory activity of the antibody is superior to that of a reference antibody such as Tezepelumab.

The present invention discloses the use of an IGF2BP2 inhibitor in the preparation of a drug for treating T-ALL, belonging to the fields of molecular biology and medicine. The invention clarifies the role of IGF2BP2 in acute T-lymphocytic leukemia, screens for drugs that specifically target and bind to IGF2BP2, and verifies their killing effect on acute T-lymphocytic leukemia cells, providing new therapeutic ideas and drugs for further improving the treatment of acute T-lymphocytic leukemia.

The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and / or lymphoproliferation.

The present invention relates to a first composition comprising one of CD4+ T cells and CD8+ T cells for use with a second composition comprising the other of CD4+ T cells and CD8+ T cells in a method for treating a subject having chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein the method comprises administering to the subject a dose of modified T cells comprising CD4+ and CD8+ T cells comprising a chimeric antigen receptor (CAR) that binds specifically to CD19, wherein: (i) the subject has relapsed following remission after treatment with, has become refractory to or has failed treatment with and / or has been intolerant to ibrutinib and venetoclax;(ii) administration comprises administering a plurality of separate compositions, wherein the plurality of separate compositions comprises the first composition comprising one of the CD4+ T cells and CD8+ T cells and the second composition comprising the other of the CD4+ T cells and CD8+ T cells, and (iii) the modified T cell dose comprises a defined ratio of CAR-expressing CD4+ cells to CAR-expressing CD8+ cells, optionally wherein the ratio is between approximately 1:3 and approximately 3:1;

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

The invention provides application of chidamide or a derivative thereof in preparation of a medicine for preventing and / or treating acute T lymphocytic leukemia. According to statistics of curative effect data of grouped clinical patients, compared with an existing treatment scheme (the curative effect is 20-30%) for treating acute T-ALL, the pharmaceutical composition provided by the invention has the advantages that the curative effect can be improved to 75%, and remarkable clinical benefits are brought.

The invention discloses application of prostaglandin PGE1 or PGE2 in preparation of a product for promoting proliferation of depleted precursor T cells. Specifically, prostaglandin PGE1 or PGE2 is added into a culture system of the T cells for culture, so that the efficiently amplified depleted precursor T cells can be obtained, meanwhile, the depletion degree of the CD8 + T cells can be inhibited, and when the prostaglandin PGE1 or PGE2 is stopped, the depleted precursor T cells can be rapidly and directionally differentiated into the CD8 + T cells. Therefore, when the prostaglandin PGE1 or PGE2 is applied to the in-vitro preparation process of adoptive T cell therapy, the total amount of CD8 + T cells can be remarkably increased, the proportion of Tpex is increased, the expression of a depletion marker is reduced, and a technical support is provided for clinical popularization of solid tumor infiltration lymphocyte therapy.

The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and / or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.